How to buy Sanofi shares | $50.78

Own Sanofi shares in just a few minutes.

Posted

Fact checked

Sanofi is a drug manufacturers—general business with stocks listed in the US. Sanofi shares (SNY) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$50.78 – a decrease of 0.14% over the previous week.

How to buy shares in Sanofi

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Sanofi. Find the share by name or ticker symbol: SNY. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Sanofi reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$50.78, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Sanofi, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Sanofi. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Sanofi share price

Use our graph to track the performance of SNY stocks over time.

Sanofi shares at a glance

Information last updated 2020-09-25.
Latest market closeUSD$50.78
52-week rangeUSD$37.62 - USD$55
50-day moving average USD$51.112
200-day moving average USD$49.1014
Target priceUSD$61.38
PE ratio 9.7201
Dividend yield USD$1.7 (3.35%)
Earnings per share (TTM) USD$1.94

Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.

eToro Share Trading (US stocks)

USD 0

Standard brokerage - US shares

Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.

  • $0 brokerage for US stocks
  • Trades starting from $50
  • Fractional shares
  • Copy top traders
Go to site
More info

Important: Share trading carries risk of capital loss.

Promoted

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Data indicated here is updated regularly
Name Product Standard brokerage for US shares Inactivity fee Currency conversion fee Markets
eToro Share Trading (US stocks)
USD 0
USD 10 per month if there’s been no login for 12 months
0.50%
Forex, CFDs, US shares
Zero brokerage share trading on US stocks with trades as low as $50.
Note: This broker offers CFDs which are volatile investment products and most clients lose money trading CFDs with this provider.
Join the world’s biggest social trading network when you trade stocks, commodities and forex from the one account.
IG Share Trading
Finder Award
IG Share Trading
USD 0
AUD 50 per quarter if you make fewer than three trades in that period
0.70%
ASX shares, Global shares, Forex, CFDs, Margin trading
Brokerage discount: $5 on Australian shares for active traders & $0 commission on US and global shares
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, forex and CFDs, plus get access to 24-hour customer support.
CMC Markets Stockbroking
USD 0
No
0.60%
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, mFunds
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, managed funds, forex, commodities and cryptocurrencies, plus access up to 15 major global and Australian stock exchanges.
loading

Compare up to 4 providers

Is it a good time to buy Sanofi stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Sanofi price performance over time

Historical closes compared with the close of $50.78 on 2020-09-25

1 week (2020-09-24) -0.02%
1 month (2020-09-01) 1.68%
3 months (2020-07-01) -0.96%
6 months (2020-04-01) 18.34%
1 year (2019-10-01) 12.39%
2 years (2018-10-01) 12.84%
3 years (2017-09-29) 1.99%
5 years (2015-10-01) 6.79%

Is Sanofi under- or over-valued?

Valuing Sanofi stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sanofi's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Sanofi's P/E ratio

Sanofi's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 10x. In other words, Sanofi shares trade at around 10x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Sanofi's PEG ratio

Sanofi's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.8375. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sanofi's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Sanofi financials

Gross profit TTM US$25.7 billion
Return on assets TTM 4%
Return on equity TTM 18.62%
Profit margin 29.28%
Book value 26.249
Market capitalisation US$127.6 billion

TTM: trailing 12 months

Shorting Sanofi shares

There are currently 3.3 million Sanofi shares held short by investors – that's known as Sanofi's "short interest". This figure is 5% down from 3.5 million last month.

There are a few different ways that this level of interest in shorting Sanofi shares can be evaluated.

Sanofi's "short interest ratio" (SIR)

Sanofi's "short interest ratio" (SIR) is the quantity of Sanofi shares currently shorted divided by the average quantity of Sanofi shares traded daily (recently around 1.1 million). Sanofi's SIR currently stands at 3.04. In other words for every 100,000 Sanofi shares traded daily on the market, roughly 3040 shares are currently held short.

However Sanofi's short interest can also be evaluated against the total number of Sanofi shares, or, against the total number of tradable Sanofi shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sanofi's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Sanofi shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Sanofi shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sanofi.

Find out more about how you can short Sanofi stock.

Sanofi share dividends

35%

Dividend payout ratio: 35.3% of net profits

Recently Sanofi has paid out, on average, around 35.3% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.35% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Sanofi shareholders could enjoy a 3.35% return on their shares, in the form of dividend payments. In Sanofi's case, that would currently equate to about $1.7 per share.

While Sanofi's payout ratio might seem fairly standard, it's worth remembering that Sanofi may be investing much of the rest of its net profits in future growth.

Sanofi's most recent dividend payout was on 25 May 2020. The latest dividend was paid out to all shareholders who bought their shares by 29 April 2020 (the "ex-dividend date").

Have Sanofi's shares ever split?

Sanofi's shares were split on a 5:1 basis on 29 September 2013. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Sanofi shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Sanofi shares which in turn could have impacted Sanofi's share price.

Sanofi share price volatility

Over the last 12 months, Sanofi's shares have ranged in value from as little as US$37.62 up to US$55. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sanofi's is 0.3849. This would suggest that Sanofi's shares are less volatile than average (for this exchange).

Sanofi overview

Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; and Kymera Therapeutics. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Frequently asked questions

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site